

04th May, 2019

The Dy. General Manager (Listing Dept.)
 BSE Limited.,
 Corporate Relationship Dept.,
 1st Floor, New Trading Ring,
 P. J. Towers, Dalal Street, Fort,
 Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
 National Stock Exchange of India Ltd.,
 Exchange Plaza, 5th Floor,
 Plot No. C/1, G. Block,
 Bandra - Kurla Complex, Bandra (E),
 Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Intimation regarding issue of Commercial Papers

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company has issued Commercial Paper (“CPs”) for an amount of ₹ 200 Crores (Rupees Two Hundred Crores Only) on 03rd May, 2019. Details of the same are as follows:

Issue size	₹ 200 crores
Listing of Commercial Papers	CPs are not proposed to be listed
Tenure of the instrument	136 days
Date of Allotment	03 rd May, 2019
Date of Maturity	16 th September, 2019
Coupon/ Interest offered	7.75% per annum
Schedule of payment of Interest	Payment on maturity i.e. 16 th September, 2019
Schedule of payment of Principal amount	Payment on maturity i.e. 16 th September, 2019
Charge / Security	Unsecured
Special right / interest / privileges attached	No special rights attached to CPs
Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal	Not Applicable
Details of any letter or comments regarding payment / non payment of interest, principal on due dates, or any other matter concerning the security and / or the assets along with its comments thereon, if any.	Not Applicable

ICRA Limited has granted rating of A1+ for issuance of Commercial papers by the Company.

The above is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
 VP (LEGAL) & COMPANY SECRETARY